Digital biomarkers for dementia are measurable physical or biological indicators detected through digital devices—such as smartphones, wearables, or computer-based tests—that reveal changes in the brain associated with cognitive decline. Unlike traditional blood tests or imaging studies that require a doctor’s office visit, digital biomarkers can be tracked continuously or during routine daily activities, offering earlier signals of dementia risk before memory problems become obvious. For example, changes in how someone types on a keyboard (slower speed, more errors) or patterns in how they sleep (tracked by a smartwatch) have emerged as early warning signs researchers can now detect and monitor. These biomarkers work because dementia affects not just memory, but motor control, sleep architecture, gait stability, and even eye movement patterns.
A person with early Alzheimer’s disease might not feel forgetful yet, but a digital test measuring how quickly they can tap their fingers in a specific pattern, or how they navigate an obstacle course on a tablet, can reveal cognitive changes months or years before traditional cognitive testing. This shift from waiting for noticeable symptoms to detecting biological signals in advance is reshaping how researchers and clinicians think about early intervention. The promise of digital biomarkers is real—they’re accessible, low-cost to deploy at scale, and generate continuous data that paints a fuller picture of brain health than a single annual visit. However, they come with limitations. Most digital biomarkers studied so far lack the clinical validation that established medical tests have, and not all wearables or apps measure what they claim.
Table of Contents
- WHAT COUNTS AS A DIGITAL BIOMARKER FOR DEMENTIA?
- HOW DIGITAL BIOMARKERS DIFFER FROM TRADITIONAL TESTS
- SPECIFIC DIGITAL BIOMARKERS SHOWING PROMISE IN RESEARCH
- HOW TO INTERPRET DIGITAL BIOMARKER DATA AT HOME
- VALIDATION CHALLENGES AND WHAT’S NOT YET PROVEN
- DIGITAL BIOMARKERS IN CLINICAL TRIALS AND RESEARCH
- INTEGRATING DIGITAL BIOMARKERS INTO DEMENTIA CARE PLANNING
- Frequently Asked Questions
WHAT COUNTS AS A DIGITAL BIOMARKER FOR DEMENTIA?
A digital biomarker is any measurable change detected by an electronic device that correlates with dementia risk or progression. The key word is “measurable”—it has to produce data, not just an impression. A smartwatch that tracks heart rate variability, an app that times how fast someone solves puzzles, or a motion sensor that measures gait speed are all collecting data that researchers can analyze. In contrast, a person simply noticing they feel forgetful is a symptom, not a biomarker. Researchers have identified several categories of digital biomarkers worth monitoring. Cognitive biomarkers measure mental processing (reaction time, decision-making speed).
Motor biomarkers track physical movement (tremor, gait instability, finger-tapping speed). Sleep biomarkers monitor rest patterns and deep sleep duration. Physiological biomarkers measure heart rate variability, blood pressure patterns, or subtle changes in voice quality. A single device like a smartphone or smartwatch can sometimes capture multiple categories at once—a smartwatch worn overnight picks up sleep patterns, heart rate, and movement. One practical example: the UK Biobank has deployed a smartphone app that asks users to perform simple tasks—tapping in rhythm, speaking short phrases, balancing on one leg—and records the results. Early data suggest that faltering balance or vocal changes appear in people who later develop mild cognitive impairment, even when they report no memory problems. This is the value of digital biomarkers: they catch what the person hasn’t noticed yet.
HOW DIGITAL BIOMARKERS DIFFER FROM TRADITIONAL TESTS
A traditional cognitive test—like the Montreal Cognitive Assessment (MoCA) or Mini-Cog—happens in a clinic on a single day. A neuropsychologist asks the patient to answer questions, draw shapes, or recall words. The result is a score, and the test is over until the next annual or semi-annual appointment. Digital biomarkers flip this model: they work best when they’re repeated frequently, even daily, so researchers and clinicians can track trends over months or years. This continuous measurement reveals patterns that a single snapshot cannot. someone might score normally on a clinic cognitive test but show a steady decline in typing speed captured by a keyboard-monitoring app over six months—a more sensitive early-warning signal. However, this strength is also a weakness. Digital biomarkers produce a lot of noise.
A person might type slowly one day because they’re tired, or their smartwatch might misread their heart rate if they’re exercising. Sorting true biological decline from daily variation requires sophisticated statistical methods and large datasets, which most clinical practices don’t have yet. Another key difference: accessibility. A smartwatch-based gait biomarker can be deployed to thousands of people remotely. A brain MRI requires a hospital appointment and costs hundreds of dollars. Yet traditional imaging directly shows brain changes—shrinkage, plaques, tangles—while digital biomarkers are indirect proxies. A change in finger-tapping speed suggests cognitive change, but it doesn’t prove what’s happening in the brain. This gap between what we can detect and what we fully understand remains a significant limitation.
SPECIFIC DIGITAL BIOMARKERS SHOWING PROMISE IN RESEARCH
Several digital biomarkers have moved beyond early research and shown clinical potential. Voice analysis is one. Researchers at Massachusetts Eye and Ear published work showing that subtle changes in voice—particularly reductions in pitch variation and speech rate—correlate with cognitive decline. A person might not notice they’re speaking more monotonously, but an audio-processing algorithm can detect it. The advantage is that voice data can be collected during a phone call or through a smartphone app; no special hardware needed. Gait biomarkers are another example. Multiple studies have found that dementia correlates with slower walking speed, wider stride variability, and loss of the normal arm swing.
A smartwatch with an accelerometer, or even a pressure-sensitive floor mat at home, can measure these changes. One large study found that gait changes preceded cognitive decline by 1-2 years in some participants, making it a potential early-warning signal. The limitation is that gait changes can also result from arthritis, vision loss, or other conditions unrelated to dementia, so gait alone is not specific enough to diagnose dementia—it’s one piece of a puzzle. Sleep biomarkers derived from smartwatches or bed-based sensors are emerging as well. Research suggests that dementia is associated with more fragmented sleep, shorter REM sleep duration, and disrupted circadian rhythms—all measurable by wearables. Unlike a sleep study in a lab (which is uncomfortable and expensive), a smartwatch continuously monitors sleep over weeks. The challenge is that smartwatch sleep estimates often differ from the clinical gold standard (polysomnography) by 30-60 minutes, so the data is approximate rather than precise.
HOW TO INTERPRET DIGITAL BIOMARKER DATA AT HOME
If you’re tracking digital biomarkers yourself—using a smartwatch, a cognitive app, or a home monitoring device—knowing what changes matter is critical. A single day of poor sleep or slower typing isn’t a red flag. Dementia develops gradually, and biomarkers gain meaning only when they show a trend: decline over weeks and months, not hours or days. One practical approach: establish a baseline. If you’re tracking finger-tapping speed using a smartphone app, perform the test 3-5 times over a baseline week when you’re well-rested and not under stress, and record the average. Then test weekly.
If your average speed drops by 10-15% over two months with no obvious explanation (like a hand injury), that warrants a conversation with your doctor. If it fluctuates up and down within 5-10%, that’s normal daily variation. However, here’s the tradeoff: home-based digital biomarkers work best as conversation starters with your doctor, not as self-diagnoses. An app that tells you your “dementia risk score is 73%” based on tapping speed is not validated and could cause unnecessary alarm. Most such apps are marketing tools, not clinically validated tests. In contrast, a structured digital biomarker collected as part of a research study—where trained staff have validated the device, standardized the protocol, and analyzed the data with rigorous statistics—holds much more weight.
VALIDATION CHALLENGES AND WHAT’S NOT YET PROVEN
The biggest limitation of digital biomarkers is that most are not yet validated for clinical use. “Validated” means: multiple independent research teams have tested the biomarker in large populations, shown it predicts actual dementia diagnosis or progression reliably, and a regulatory body (like the FDA) has reviewed and approved it. Most digital biomarkers fall short of this standard. They show correlation in one study but may not replicate in another population, or the replication study includes different devices or protocols. A warning: if a company selling a smartwatch app or home device claims their digital biomarker can “detect dementia early” or “predict your dementia risk,” ask for peer-reviewed published evidence in a reputable journal, and check whether the study was funded by the company. Many commercial products make claims that far outpace their evidence.
A smartwatch that accurately tracks heart rate doesn’t mean its built-in “brain health score” is validated. The heart rate tracking might be solid; the brain health score is often a proprietary calculation with no published validation. Another validation issue is demographic bias. Most digital biomarker research so far has been conducted on educated, white, relatively affluent populations who own smartphones and smartwatches. A biomarker validated in such a group might behave differently in other populations—it might be more or less sensitive, or it might be confounded by different factors. This means that even “validated” biomarkers may not work equally well for everyone.
DIGITAL BIOMARKERS IN CLINICAL TRIALS AND RESEARCH
Pharmaceutical companies and academic medical centers are now using digital biomarkers to recruit and monitor participants in dementia drug trials. Instead of waiting months between clinic visits to assess whether an experimental drug is working, researchers can deploy a smartwatch-based gait monitor or a smartphone app that measures cognitive speed daily. This allows them to detect drug effects faster and with more granular data.
A concrete example: a recent trial of a new Alzheimer’s drug used a smartphone app to measure reaction time and attention span weekly, rather than relying only on clinic-based testing every three months. The weekly digital data showed a slowing of cognitive decline earlier than the quarterly clinic visits would have detected, potentially allowing researchers to optimize the drug dose or identify responders versus non-responders faster. This kind of real-time data is reshaping trial design and could accelerate the development of new treatments.
INTEGRATING DIGITAL BIOMARKERS INTO DEMENTIA CARE PLANNING
For someone already diagnosed with mild cognitive impairment or dementia, digital biomarkers offer a way to track disease progression and monitor responses to interventions—whether drugs, cognitive training, or lifestyle changes. A person on a new dementia medication can use a smartwatch to monitor sleep quality, gait stability, and heart rate patterns over weeks, generating objective data on whether the medication is helping. This is more informative than asking a patient, “Do you feel better?” at an office visit three months later.
The practical reality is that most neurologists and primary care doctors are not yet equipped to interpret digital biomarker data in their daily practice. The tools exist, but the clinical infrastructure to support them—the time, the software to display the data, the training for doctors to make sense of it—is still developing. Over the next few years, expect electronic health records to integrate more digital biomarker data, and expect more doctors to receive training in interpreting trends from wearables and apps. For now, digital biomarkers work best when integrated into research studies or specialized memory clinics, not routine primary care.
- —
Frequently Asked Questions
Can I use a smartwatch to detect dementia in myself or a family member?
A smartwatch tracks data like heart rate, sleep, and movement, but interpreting that data requires clinical expertise. Some patterns (slower gait, fragmented sleep) correlate with cognitive decline, but they’re not specific to dementia—they can result from many conditions. Use smartwatch data as background information for your doctor, not as a self-diagnosis tool. Avoid apps claiming to “predict” or “detect” dementia unless they cite peer-reviewed validation studies.
Are digital biomarkers more accurate than cognitive tests like the Mini-Cog?
No, not yet. Traditional cognitive tests like the MoCA have been used for decades and are well-validated. Digital biomarkers are promising for earlier detection and continuous monitoring, but most lack the clinical validation of traditional tests. Think of digital biomarkers as a complementary tool—they might catch changes earlier, but they work best alongside, not instead of, standard medical evaluation.
How often should digital biomarkers be measured?
That depends on the biomarker and the context. Smartwatch data (gait, sleep, heart rate) are typically useful when collected daily or several times weekly over weeks to months, so trends become visible. Cognitive testing apps might be used weekly or monthly. A single measurement is almost meaningless; the value is in the trend. Discuss with your doctor how often makes sense for your situation.
Will insurance cover digital biomarker monitoring?
Currently, most insurance does not reimburse for digital biomarker data collection or analysis. Wearable devices (smartwatches, fitness trackers) are consumer purchases. Some research studies offer them free to participants. As digital biomarkers become more validated and integrated into clinical care, insurance coverage may follow, but this is a developing area.
What’s the difference between a digital biomarker and a fitness tracker?
A fitness tracker (like a standard smartwatch) collects data on activity, heart rate, and sleep primarily for wellness marketing. A digital biomarker is a specific, validated measurement of a biological change related to disease risk. A smartwatch *could* generate digital biomarker data if the device, the measurement protocol, and the statistical analysis meet research standards—but the fitness app that comes with the watch typically does not.
Can digital biomarkers replace doctor visits?
No. Digital biomarkers are tools for monitoring and early detection, not replacements for clinical evaluation. A person with changes in voice, gait, or sleep patterns still needs a neurological examination, cognitive testing, imaging, and blood work from a qualified clinician to determine the cause. Digital biomarkers should prompt a doctor visit, not delay one. —
